Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

Clinical trial NCT06160843 · RECRUITING

Trial details

NCT number: NCT06160843
Sponsor: National Cancer Centre, Singapore
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed Peripheral T-Cell Lymphoma Refractory Peripheral T-Cell Lymphoma

Start date: 2024-07-01
Primary completion: 2028-01-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.